Team:AFCM-Egypt
Neo-Epitope Discovery for DNA-launched RNA Replicons:
Paving The Way To Effcient Breast Cancer Vaccination
Triple negative breas cancer is one of the mos aggressive breas cancer subtypes. It is characterized by a generally poor prognosis and srong resisance to traditional therapies. In the frs Phase of our project, we focused on designing a novel immunotherapeutic approach using DNA-launched RNA Replicons (DREP). We utilized our hotspot detection tool, “Cusommune”, to generate a lis of candidate neo-epitopes, validated them in silico, modeled the behavior of our suggesed circuits and optimized them to ensure maximal safety and efcacy.
Retrieval of TNBC patients neo-mutations within prioritized set of HotSpot Antigens followed by epitope-prediction by Custommune and final vaccine design.
Delivery of the Replicon-based DNA vaccine to host cells (e.g. myocytes) carrying potential epitopes.
Release of exosomes and apoptotic bodies carrying the expressed epitope-based vaccine leading to TLR recognition stimulating innate immunity.
Dendritic cells recognition of expressed epitopes and IFN response.
Dendritic cells present the epitopes to Cytotoxic T-lymphocytes and T-helper cells stimulating cell- mediated immunity.
Recruitment and stimulation of B cells and antibody response.
Recognition and attack of Triple-negative breast cancer cells.
